Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

VOLUNTARY ANNOUNCEMENT

HX111 COMPLETES FIRST PATIENT DOSING

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**") on a voluntary basis.

The Board is pleased to announce that the Company has initiated the Phase I clinical trial of HX111, the Company's independently developed candidate drug (an OX40-targeting antibody-drug conjugate ("**ADC**") candidate drug), for the treatment of relapsed/refractory lymphoma and solid tumors, and has successfully completed the first patient enrollment and dosing in the recent period.

HX111 binds to the OX40 molecule on the surface of tumor cells with high affinity and high specificity. After being efficiently internalized into tumor cells via endocytosis, the linker is cleaved by lysosomal proteases, releasing a potent payload, thereby inducing tumor cell apoptosis. The OX40 molecule is highly expressed in certain lymphoma and solid tumors, for which there are currently limited effective treatment options, leaving a significant unmet clinical need. HX111, developed by the Company, is the first OX40-targeted ADC drug worldwide to have publicly entered the clinical stage (First-in-Class, FIC). This field remains in its early exploratory stages, and HX111 holds a significant first-mover advantage, with the potential to fill the gap in the treatment of such tumors in the future.

Warning: HX111 may not ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing the Company's shares.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, 4 February 2026

As at the date of this announcement, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian and Ms. Xiao Jieyu as non-executive Directors; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.